Our regular monthly PCSO meeting for October will be at the Ottawa Cancer Foundation’s Maplesoft-Jones Centre [MAP] on 16 October 2025, starting at 6:00 pm. Our guest speaker will be Dr. Michael Ong, medical oncologist and associate professor at the Ottawa Hospital.
We also will be welcoming Mr. Larry Trickey to this meeting. Larry successfully underwent immunotherapy for his prostate cancer under Dr. Ong’s care. Click on this link to read the remarkable story of Larry’s immunotherapy journey.
To attend in person
- Please register early by e-mail at: .(JavaScript must be enabled to view this email address), and please ensure that you include the number of attendees in your party.- By email, we’ll either confirm your reservation, or advise you that we’ve reached the Centre’s capacity of 24 persons.
Note: Masks are not mandatory but are recommended in the Maplesoft-Jones Centre
To attend virtually by Zoom
- To register, please click on this link. After registering, you’ll receive an email with instructions for joining the meeting.
Our Guest Speaker Dr. Michael Ong
Using Immunotherapy to Treat Prostate Cancer
Fighting the good fight on the lab bench or at the patient bedside: Dr. Michael Ong is an oncologist and associate professor at The Ottawa Hospital who has spent his career discovering new therapies against cancer by enrolling patients in clinical trials. His research and practice have focussed on prostate cancer, bladder cancer, and melanoma, and over the last decade he has been the lead investigator in Ottawa for countless clinical trials. He currently leads several national and international clinical trials that are poised to change how we treat cancer, including how we use cancer immunotherapy, where a patient’s own immune system is harnessed to attack cancer. Dr. Ong’s research is changing the way care is delivered at The Ottawa Hospital, and far beyond.
Curling News
Not sure where to start?
We are only a phone call or email away. Contact PCSO anytime at 613-828-0762 or .(JavaScript must be enabled to view this email address).
